HC Wainwright Issues Optimistic Outlook for RAPP Earnings

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings estimates for Rapport Therapeutics in a research note issued on Wednesday, March 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.65) for the quarter, up from their previous estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.40) EPS, FY2027 earnings at ($3.56) EPS, FY2028 earnings at ($4.65) EPS and FY2029 earnings at ($4.78) EPS.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07).

Several other research firms have also issued reports on RAPP. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen raised Rapport Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research report on Monday. Finally, Wells Fargo & Company lifted their price target on Rapport Therapeutics from $43.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Rapport Therapeutics Stock Down 6.1%

Shares of NASDAQ:RAPP opened at $28.67 on Friday. The stock has a market cap of $1.37 billion, a PE ratio of -10.02 and a beta of 1.51. The company’s fifty day moving average is $28.11 and its 200 day moving average is $26.90. Rapport Therapeutics has a 52 week low of $7.73 and a 52 week high of $42.27.

Insider Activity

In other news, CEO Abraham Ceesay sold 5,083 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.36, for a total transaction of $149,236.88. Following the completion of the sale, the chief executive officer directly owned 20,729 shares in the company, valued at approximately $608,603.44. This represents a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Cheryl Gault sold 2,014 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $28.93, for a total value of $58,265.02. Following the completion of the sale, the chief operating officer directly owned 169,914 shares in the company, valued at $4,915,612.02. The trade was a 1.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 69,669 shares of company stock worth $1,999,877 in the last quarter. Insiders own 13.57% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after buying an additional 4,582 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new stake in shares of Rapport Therapeutics in the 1st quarter worth approximately $2,039,000. Rhumbline Advisers increased its stake in shares of Rapport Therapeutics by 40.1% during the first quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after buying an additional 4,109 shares during the period. Geode Capital Management LLC raised its holdings in shares of Rapport Therapeutics by 5.5% during the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock valued at $3,789,000 after acquiring an additional 17,496 shares in the last quarter. Finally, Creative Planning bought a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $121,000.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy and raised multiple near-term EPS forecasts (Q1–Q4 2026 and FY2026–2028), marking sizeable improvements to FY2026 (from -$3.16 to -$2.40) and trimming some later-year losses — this supports a constructive view on RAP-219 development progress and a $40 price target. Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
• Positive Sentiment: Wells Fargo raised its price target to $46 and assigned an “overweight” rating — a higher target from a major bank can boost investor confidence and act as support for the stock. Wells Fargo raises price target
• Neutral Sentiment: HC Wainwright provided longer-term FY2029/FY2030 estimates (mixed changes across distant years) — useful for modeling but less likely to drive near-term moves compared with the recent earnings print and near‑term guidance. Analyst long-term estimates
• Neutral Sentiment: A regulatory filing/annual report notice (non-U.S.) appeared in the feed but is not clearly related to RAPP’s U.S. operations or clinical program timelines — likely immaterial to near-term U.S. trading. Mise à disposition des éléments préparatoires
• Negative Sentiment: RAPP reported quarterly results that missed estimates (reported EPS of -$0.72 vs. consensus -$0.65), and the shares gapped down after that print — the earnings miss is the primary near-term catalyst putting downward pressure on the stock. Rapport Therapeutics Shares Gap Down After Earnings Miss

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.